Professor Dean Ho, Director of the NUS Singapore Institute for Neurotechnology (SINAPSE), and Assistant Professor Edward Chow from the Cancer Science Institute of Singapore (CSI), have created an artificial intelligence system which optimises drug selection and dosage to improve treatment of diseases. Both professors are also from the Department of Pharmacology at NUS Medicine.
The developed platforms called QPOP (Quadratic Phenotypic Optimisation Platform) and CURATE.AI have benefited more than 30 patients who were treated for cancers, infectious diseases, cognitive training for brain function improvements. The platforms work in tandem, and are formulated to ensure efficacy and safety in the combination of the selected drugs and dosages for each patient, based on their clinical data, biomarkers and indicators. Information gathered from the patients would eventually lead to an individualised CURATE.AI profile, and the programme continuously monitors the patients’ responses to the drugs and dosages, providing information that indicates the best possible treatment outcome at any point in time.
“We’re addressing what had previously been thought to be impossible. We’re finding out the right drugs at the right dose for an individual in a sustained fashion,” said Prof Ho.
The team has also been working with overseas treatment centres and medicine colleges on exploratory trials, and it will soon be used by National University Cancer Institute (NCIS) for a clinical trial involving multiple myeloma patients in June. The team is recruiting 195 participants for three clinical trials in multiple myeloma treatment, liver transplant immunosuppression and cognitive training.